NCT04529954View on ClinicalTrials.gov

Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Focal Epilepsy
Interventions
DRUG

Valproic Acid delivered to ICV

Valproic Acid delivered to ICV via an implantable pump and catheter system

Trial Locations (8)

Unknown

Mater Brisbane, Brisbane

RBWH, Brisbane

SVHM, Melbourne

The Alfred, Melbourne

The Austin, Melbourne

Hadassah Medical Center, Jerusalem

Sheeba Medical Center, Jerusalem

Tel Aviv Sourasky Medical Center, Tel Aviv

Sponsors
All Listed Sponsors
lead

Cerebral Therapeutics LLC

INDUSTRY

NCT04529954 - Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion | Biotech Hunter | Biotech Hunter